)
)
)
Evecxia Therapeutics
EVX-101 could emerge as one of the most impactful psychiatric drugs since Prozac® – given:
- Safety
- No abuse
- Scalability within existing care and reimbursement infrastructure
- Risk-mitigated clinical rationale
- Multiple large indications
Evecxia is the first company realizing the therapeutic potential of Serotonin Synthesis Amplification—creating a stronger, more resilient brain serotonin system—a pharmacology distinct from SSRIs (eg Prozac) and psychedelics.
Fifty years of clinical evidence support that Serotonin Synthesis Amplification can safely augment therapeutic efficacy in psychiatric patients when SSRI monotherapy is inadequate.
Lead asset EVX-101—a safe oral tablet—to enter Phase 2 POC trial in OCD in 2026.
Second asset EVX-301 dosing Q1 2026 in a Phase 1b target engagement trial using gold-standard biomarkers of brain Serotonin Synthesis Amplification.
Address
North CarolinaUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)